---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-014572"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T01:20:28.160915+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Reviva Q1 net loss $6.6M; cash to fund ops through Q3 2023; Phase 3 topline data mid-2023

## Summary
- Net loss of $6.6M ($0.30/shr) vs $7.4M ($0.40) in Q1 2022; cash $11.3M at Mar 31, 2023, down from $18.5M.
- Cash sufficient to fund current plans through Q3 2023; additional financing needed for Phase 2a studies.
- Over 60% of ~400 patients enrolled in Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.
- Brilaroxazine lipogel showed proof-of-concept in psoriatic mouse model; IND for psoriasis expected in 2024.
- May initiate Phase 2a studies in bipolar, MDD, and ADHD in H2 2023 subject to additional financing.

## SEC filing metadata
- accession: 0001437749-23-014572
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/0001437749-23-014572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/rvph20230512_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-014572
- JSON: https://secwatch.observer/filing/0001437749-23-014572.json
- Plain text: https://secwatch.observer/filing/0001437749-23-014572.txt

## Key facts
- Earnings Releases
  REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the first quarter ended March 31, 2023 results: net income approximately $6.6 million, EPS $0.30 per share.
  - Period: the first quarter ended March 31, 2023
  - Net income: approximately $6.6 million
  - EPS: $0.30 per share
  - Result: reported results
  source text: The Company reported a net loss of approximately $6.6 million, or $0.30 per share, for the three months ended March 31, 2023, compared to a net loss of approximately $7.4 million, or $0.40 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1742927/000143774923014572/0001437749-23-014572-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.